chrisvoncsefalvay/vaers-outcomes huggingface dataset:
has psoriasis which was pretty much under control until they received the vaccine; dizziness; rash on both legs and both arms; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (has psoriasis which was pretty much under control until they received the vaccine), DIZZINESS (dizziness) and RASH (rash on both legs and both arms) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19. Concurrent medical conditions included Psoriasis. Concomitant products included TAMSULOSIN for an unknown indication.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PSORIASIS (has psoriasis which was pretty much under control until they received the vaccine), DIZZINESS (dizziness) and RASH (rash on both legs and both arms). The patient was treated with IXEKIZUMAB (TALTZ) ongoing since an unknown date for Psoriasis, at a dose of 1 dosage form. At the time of the report, PSORIASIS (has psoriasis which was pretty much under control until they received the vaccine) had not resolved and DIZZINESS (dizziness) and RASH (rash on both legs and both arms) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment included topical cream   Most recent FOLLOW-UP information incorporated above includes: On 20-Jun-2021: TCR Form received on 20-JUN-2021:treatment medication, event outcome updated
After the 2nd vaccine, I traveled, when I got home I noticed I lost my sense of taste and smell. I could not see the doctor at that time and I could not test for COVID-19. 03/26/2021 I noticed I could not eat anything, with high fat content, like french fries, cheese curd and potatoes chips. My symptoms were that approximately an hour after eating potato chips I had a bowel movement. It just made my GI tract convulse. My thighs started to hurt and the doctor said it sounded like vitamin D deficiency. And prescribed 25 mcg of vitamin D-3, twice a day. The pain in my thighs went away. My stomach problems never went away. I noticed blood in my stool. I thought it was related to hemorrhoids. I got my booster on September 29, 2021, and in October my symptoms got much worse. It did not matter if I had something greasy, I would just seem like I would have a bowel movement like 2 or 3 times a day, which was unusual. I had a colonoscopy in November, they only found 1 polyp. They also said my hemorrhoids were non-bleeding and were not flared up. I had to stop drinking coffee. I stopped my magnesium. After the colonoscopy the symptoms got terrible. I thought I was managing, then I got food poisoning 12/23/2021. I was recovering on 12/24/2021. Then after Christmas, 12/25/2021, I got the worse flare up. I had pain and blood. I went to see my doctor, on 12/27/2021 and they started treating me for IBS and put me on a FODMAP diet. It's been a week on the diet and I have no pain, no blood. I think the doctor diagnosed it correctly.
Vaccines were administered. Patient stated that she didn't like vaccines and then passed out. She lost consciousness for about 5 seconds. She fell from the chair she was sitting in to the floor. After a minute of sitting on the floor patient was able to sit in the chair. Patient appeared pale. Vital signs were 102/72, P 65 O2 96 R 16. Patient sipped some juice and reported feeling less light headed. Stated she didn't have any injuries from the fall.
Major headaches/headache is still really bad; Nausea; Granulocytes were high at 81.2; Lymphocyte number was low at 0.9; This spontaneous case, initially received on 18-Oct-2018, from other health professional, concerning a 64-year-old, adult female patient.  The patient had no medical history and the concomitant medications included aspirin, calcium carbonate and acetaminophen for unknown indications.  On 16-Oct-2018, the patient was administered Afluria Quadrivalent [influenza vaccine, dose: 0.5 ml, route of administration: intramuscular, anatomical location: left deltoid, batch number: YF41508 and expiry date: 30-Jun-2019] for influenza prophylaxis.  On 17-Oct-2018, 1 day after vaccination, the patient experienced major headache and nausea. On the same day, the patient was taken to the emergency room (ER) and treated with normal saline (1000 ml intravenous), ketorolac (30 mg, intravenous) and Zofran (ondansetron, 4 mg injection). On the same day, at 14:30 pm, the patient received another injection of ketorolac. The complete blood tests (CBC) (CVC as reported), comprehensive metabolic panel (CMP) tests and C-reactive protein tests were performed and granulocytes were 81.2 (elevated) and lymphocytes were 0.9 (depressed) (units not reported). All other tests were found to be normal. On 18-Oct-2018, the patient was taken to ER again and treated with prochlorperazine (prochlorperazine maleate, 5 mg, intravenous), ketorolac (30 mg, intravenous) and Benadryl injection (diphenhydramine hydrochloride, 50 mg in 100 ml solution, intravenous). The patient also continued Zofran (orally). On the same day, computed tomography (CT) scan of head was ordered and the patient sent to home with a prescription of Phenergan 25 mg. It was reported that, the patient still felt really bad headache.    At the time of this report, the patient had not recovered from the event headache and outcome of the event nausea was not reported. The outcome of the events (granulocyte count high and lymphocyte count low) was unknown.  The reporter assessed the case as serious (medically significant).; Reporter's Comments: A 64-year-old, adult female patient experienced headache, nausea one day after receipt of Afluria QIV vaccine. Considering the plausible temporal relationship between vaccination and reported events, plausible biological mechanism and lack of any underlying conditions or alternative more plausible causes, the company assesses the events as possibly related to suspect vaccine.
sz-non responsive-eyes glazed;amb called;incident lasted approx 7min;starting to respond when EMS arrived;?epilepsy diagnosis;Annual follow-up dated 12/14/00 provided no additional data.
Injection site reaction. Information has been received from a registered nurse concerning a female patient (age not provided) who on unspecified date was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (lot#650331/0749P). Five days after vaccination the patient developed injection site reaction. The patient was reported as recovered. Additional information has been requested.
doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date) in a 21-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043B21A) for COVID-19 vaccination. No Medical History information was reported. On 24-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.  No concomitant medications were reported. The vial was placed in the refrigerator on 01-Mar-2022. There was no temperature excursion. It was reported that there was a confusion between the expiration date printed in the carton and the expiration date when the QR code was scanned. The patient did not experience any adverse event. Treatment information was not provided. This case was linked to MOD-2022-491837 (Patient Link).
sore bone; congested; itchiness in left and right sides, near the ribs; sore arm; headache; This spontaneous case was reported by a consumer and describes the occurrence of BONE PAIN (sore bone), FEELING ABNORMAL (congested), PRURITUS (itchiness in left and right sides, near the ribs), PAIN IN EXTREMITY (sore arm) and HEADACHE (headache) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 075C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included METFORMIN for an unknown indication.   On 24-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Jun-2021, the patient experienced BONE PAIN (sore bone), FEELING ABNORMAL (congested), PRURITUS (itchiness in left and right sides, near the ribs), PAIN IN EXTREMITY (sore arm) and HEADACHE (headache). At the time of the report, BONE PAIN (sore bone), FEELING ABNORMAL (congested), PRURITUS (itchiness in left and right sides, near the ribs), PAIN IN EXTREMITY (sore arm) and HEADACHE (headache) outcome was unknown.            The patient noted she had a temperature, however body temperature value was not provided. She did not take medication to treat the symptoms. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not applicable.
COVID-19 confirmed by positive COVID-19 test; COVID-19 confirmed by positive COVID-19 test; This is a spontaneous report from a contactable nurse (patient). A 43-year-old female patient received bnt162b2 (Pfizer-BioNTech COVID-19 vaccine), dose 2 via an unspecified route of administration on 11Jan2021 20:10 (Batch/Lot Number: EK9231, NDC numbe: 59267-1000-01) as 2nd dose, single and first dose (Lot number: EK5730) on 21Dec2020 in the left arm for Covid-19 immunization. Medical history included rheumatoid arthritis from 2007 and ongoing (diagnosed with rheumatoid arthritis when she was 27 years old, in 2007 or 2008) and ongoing immunosuppression which is related to rheumatoid arthritis. Concomitant medications included hydroxychloroquine sulfate (PLAQUENIL S); bioflavonoids nos, calcium ascorbate, hesperidin, rutoside, sodium ascorbate, zinc amino acid chelate (VITAMIN C 1000 PLUS ZINC & BIOFLAVONOIDS); zinc chloride; calcium carbonate, colecalciferol (VITAMIN D 2000); naphazoline hydrochloride (EYE DROPS [NAPHAZOLINE HYDROCHLORIDE]); progesterone (PROGESTERONE) all taken for an unspecified indication, start and stop date were not reported. On 07May2021, the patient got Covid-19 after getting Covid-19 vaccine. The patient went to the Emergency Room and got an infusion by Regeneron (endevimir and casevomir) which her symptoms started improving within 5 minutes of receiving the infusion. The patient was not hospitalized/admitted to ICU. The patient did not require supplemental oxygen or receive mechanical ventilation. Patient reported that she got Covid-19 from somebody when she was in an open-air environment and her mask was off. During her Covid-19 infection, she took Benadryl 25 mg at night and Sudafed every 4 to 6 hours throughout the day. She received no sinus relief from the Benadryl or Sudafed prior to receiving the monoclonal antibody infusion. The patient display signs at rest indicative of severe systemic illness which is fever of 102 and symptoms/signs during the Covid-19 illness experience which includes dyspnea, mostly at night and had difficulty breathing due to extreme sinus congestion; diarrhea and nausea; leg pain and thought that she was getting a clot or something which patient started taking blood thinner the day after she was diagnosed with Covid-19; Covid fog where she feels really spacey and out of it and has been experiencing headaches and ears were so full that they felt like they were going to explode. The patient reported that she is still experiencing lingering effects of her Covid-19 infection - fatigue, Covid fog, and headaches. The patient underwent lab tests and procedures which included covid-19 test on 07may2021: positive and D-dimer negative on 07May2021 and basal metabolic rate on unspecified date with unknown result. The outcome of the events was recovering.  No follow-up attempts are needed. No further information is expected.; Sender's Comments: The association between the event lack of effect (COVID-19 infection) with BNT162b2 can not be fully excluded.
Pt arrived to the covid booster weekend clinic to receive her Bivalent booster.  Vaccine was given and when the vaccination card was being updated, MA saw that pt had already received a moderna booster vaccine on 9/16/22.  When discussed with pt, pt stated that she had not received the bivalent moderna booster vaccine and this was an error. "I was told I could not receive the vaccine because you guys didn't have it. Then I had another appointment scheduled, but was informed by my surgeon that I should wait for after the surgery, so here I am." Pt was due to receive vaccine at 9/8/22 OV, but order was cancelled and only influenza vaccine was give.  This RN reviewed chart more and it appears pt arrived at office for bivalent moderna booster on 9/16/22, which was schedule on 9/15/22, vaccine was given, and pt checked out.    Pt was made aware that per her chart this would be her second bivalent moderna booster and should monitor for side effects. Pt expressed understanding.    On-call provider, Dr. informed of above.    Spoke with pharmacist, who stated that pt will most likely experience side effects but otherwise should have no other complications.
76-year-old male patient of Dr. comes to ER with above complaints. Patient states his daughter was positive for COVID-19 and was and was sick. He lives with his daughter and started feeling sick about a week ago and got tested. Patient is a poor historian unable to give detailed history states he forgets. Called patient's daughter she is not available at this time spoke to patient's wife who is also on not really clear on timeline. She is also positive and tested positive after the patient which was 4 days ago. Patient reports that he he was only having mild symptoms after he tested positive but they became progressively worse to today where he was unable to take a deep breath without coughing and felt extremely fatigued and tired. Patient already had COVID-19 infection in January of 2021
Dr. ordered Dtap and changed order in the middle of med preparing and wrong vaccine was prepared and given to patient. The patient recieved an extra dose of Hep B. Dr. informed me that there would be no reactions or harm done.
Sick; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Sick) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Sick). At the time of the report, ILLNESS (Sick) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  No treatment information was provided.
30 seconds to 1 minute lapsed after shots given.  Child was standing up and crying; fell backwards into her fathers arms, convulsed (shook), eyes rolled back in head, affect of face went flat.  Event lasted 1-2 seconds.  Child was then conscious and responsive.  Father inst to call doctor.  Seizure-like activity.  The RN supervisor took over patient care immediately following the event.  Patient was placed in a supine position with legs elevated and cold packs applied to head and neck.  She remained the that position for 8-10 minutes at which time she sat in a chair and drank some coke and had some cookies.  Child left facility with father about 7 minutes later ambulatory and alert.  Multiple atempts have been made to contact parent by phone, today 10/11/07, but line consistently rings busy
This spontaneous report as received from a nurse refers to unspecified patients of unknown age and gender. The patients' medical history, concurrent  conditions and concomitant therapies were not provided. On multiple dates between 20-APR-2016 and 20-MAY-2016, the patients were vaccinated with incorrect stored doses of VAQTA for prophylaxis. The doses of VAQTA underwent temperature excursion from 47 Fahrenheit degrees to 77 Fahrenheit degrees along 32 minutes. The call was placed because of a Digital Data Logger. The VAQTA had not experienced previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same source. Sender's Comments: US-009507513-1709USA004302: US-009507513-1709USA008178: US-009507513-1709USA008179.
excessive swelling to rt muscle & upper arm;hot to touch;poss rxn to vax;poss local rxn vs infect
Shooting pain around the eyes; This case was initially received via an unknown source (no reference has been entered for a health authority or license partner) on 16-Mar-2021. The most recent information was received on 12-May-2021 and was forwarded to Moderna on 12-May-2021.    This spontaneous case was reported by a consumer and describes the occurrence of EYE PAIN (Shooting pain around the eyes) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Trigeminal neuralgia. Concomitant products included CARBAMAZEPINE and ASPIRIN [ACETYLSALICYLIC ACID] for Trigeminal neuralgia.   On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EYE PAIN (Shooting pain around the eyes). At the time of the report, EYE PAIN (Shooting pain around the eyes) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Med Info Agent: Caller returned call from Safety, updated on her state of health and updated contact information.   Patient reported that she feels fine now, her symptoms have calmed down now. She will be seeing a neurologist and has to take very high doses of medications to keep her pain under control. She reported that it took her a month to recover from the second vaccine. This case was linked to INC.-MOD-2021-077579 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 12-May-2021: Outcome of event updated.
Got the shot, Get it/ Suspected vaccination failure; Get it under the skin; This case was reported by a consumer via (Facebook) interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles was recovering/resolving.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient got the shingle shot and still got shingles again but it stayed under the skin this time and it does last a long while. The patient was just getting over shingles. This case was considered as suspected vaccination failure since the details regarding completion of primary immunization schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.
Patient received the incorrect dose of the 2023-2024 Pfizer Covid Vaccine. Patient is 4 years old on the day of vaccination. Patient received the 5?11year dose instead of the 6 months- 4 years dose.
Patient reported  dizziness 5 minutes after receiving vaccination. He remained seated, and I offered a cold compress. His symptoms resolved within 10 minutes.
1230 pt mom phoned & stated pt was c/o h/a & vomited & had an inc temp; advised to gto directly to ER or to see PMD ASAP; pt seen in L.C. hosp ER 1PM; ER md said thought it was a react to immun;
onset scattered mac-pap rash on trunk & extremities in AM p/vax afternon a/
2 3/4 x 2 red induration on right post arm, with localized heat and middle of swollen area red/purple, tender to touch. Oral Benadryl and topical hydrocortisone cream treatment.
Extreme fatigue, hard to get out of bed; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the left arm on 25Mar2021 at 15:30 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had known allergies to bell peppers and other sweet peppers. Concomitant medications included vitamin d (MANUFACTURER UNKNOWN), fluticasone propionate (FLONASE) and iron supplement; all from unknown date for unknown indication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021, the patient experienced extreme fatigue, hard to get out of bed the next day. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of extreme fatigue, hard to get out of bed were resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
This spontaneous report was received from a vaccine coordinator and refers to unspecified patients of unknown age and gender. No information about the patients' medical history, concurrent conditions, concomitant therapies, drug reactions or allergies was provided. On unknown dates in 2016, between 11-NOV-2016 and 01-DEC-2016, the patients may had been vaccinated with improperly stored VAQTA lot# reported as M026309 (verified to be invalid for VAQTA), expiration date: 24-JAN-2018 (dose, route of administration were not reported). The administered doses of vaccine were stored in the temperature of 1.1 degrees Celsius for 6 hours and 30 minutes. Previously the vaccine was improperly stored in the temperature of 1.3 degrees Celsius for 11 hours 18 minutes, in the temperature of 1.4 degrees Celsius for 5 hours 32 minutes, in the temperature of 1.5 degrees Celsius for 9 hours and 42 minutes and in the temperature of 1.1 degrees Celsius for 6 hours and 30 minutes. Cumulatively the vaccine was stored in the temperature of 1.1 degrees Celsius for 43 hours and 18 minutes. Digital data logger was involved. No adverse effects were reported. Product quality complaint was not involved. This is one of the several reports received from the same reporter. Lot number M026309 is an invalid lot number for VAQTA. Additional information has been requested. Sender's Comments: US-009507513-1612USA009210: US-009507513-1612USA001131.